Cardiovascular Outcome Trial (CVOT) summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Methodological detailsvirtual congress, 10th CVOT Summit, held virtually on December 5-6, 2024
- Virtual congress
- 10th CVOT Summit, held virtually on December 5-6, 2024
Main finding
As reported in the abstract
- Discussions centred on recent cardiovascular (CV) and kidney outcome trials: empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT) and finerenone (FINEARTS-HF)
- These studies represent significant advances in reducing major adverse cardiovascular events (MACE) risk and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD) and obstructive sleep apnea (OSA)
- Sessions on therapies for HFpEF, CKD and obesity; guidelines for CKD and MASLD; Cardio-kidney-metabolic (CKM) syndrome; precision medicine; early detection of T1D; Continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy; role of primary care; plastic pollution and cardiovascular disease (CVD) risk; incretin therapies; nutrition under incretin-based therapies
Original publication
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes. Cardiovasc Diabetol. Published 2 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →